CORT Corcept Therapeutics Incorporated

12.21
+0.55  (+5%)
Previous Close 11.66
Open 11.79
Price To Book 3.77
Market Cap 1,399,201,836
Shares 114,594,745
Volume 720,740
Short Ratio
Av. Daily Volume 1,256,276
Stock charts supplied by TradingView

NewsSee all news

  1. CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY

    MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic,

  2. Corcept Therapeutics Appoints Gregg Alton to Board of Directors

    MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  3. Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update

    MENLO PARK, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  4. Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results and provide a

  5. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

    2019 revenue of $306.5 million, an increase of 22 percent from 2018Fourth quarter revenue of $87.9 million, an increase of 32 percent from fourth quarter 2018Cash and investments at December 31, 2019, of $315.3

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 1/2 presented at ASCO June 3, 2019.
Relacorilant plus Abraxane
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Relacorilant (GRACE)
Cushing’s syndrome
Phase 2 data due 1H 2021.
Relacorilant plus Abraxane
Ovarian cancer
Phase 2 trial to be initiated in 2020.
Miricorilant
Nonalcoholic steatohepatitis (NASH)
Phase 1/2 trial to be completed by end of 2020.
Exicorilant plus Enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 2 trial to be initiated 4Q 2020.
Miricorilant
Long-standing antipsychotic-induced weight gain
Phase 3 trial planned for 2Q 2020.
Relacorilant plus nab-paclitaxel
Pancreatic cancer
Phase 2 (GRATITUDE) trial enrolling.
Miricorilant
Antipsychotic-induced weight gain (APIWG)
Phase 3 trial to commence 1Q 2020.
Relacorilant (GRADIENT)
Cushing’s syndrome
Phase 1b 900g dose data due 2Q 2020.
Miricorilant
Healthy volunteers
Phase 1b trial to be initiated 2Q 2020.
Relacorilant plus Keytruda
Adrenocortical cancer

Latest News

  1. CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY

    MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic,

  2. Corcept Therapeutics Appoints Gregg Alton to Board of Directors

    MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  3. Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update

    MENLO PARK, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  4. Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results and provide a

  5. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

    2019 revenue of $306.5 million, an increase of 22 percent from 2018Fourth quarter revenue of $87.9 million, an increase of 32 percent from fourth quarter 2018Cash and investments at December 31, 2019, of $315.3

  6. Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update

    MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  7. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 7, 2019.

  8. Corcept Therapeutics Appoints Kimberly Park to Board of Directors

    MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  9. Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing's Syndrome

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent